Examkin

Question

Difficulty: HardBreast Disorders

A 62-year-old postmenopausal woman is diagnosed with a 1.8-cm, estrogen receptor-positive, progesterone receptor-positive, HER2-negative invasive ductal carcinoma of the right breast via core needle biopsy. Clinical examination and preoperative imaging reveal no evidence of axillary lymphadenopathy or distant metastases. The patient elects to undergo breast-conserving therapy. Arrange the following management and therapeutic steps in the most appropriate chronological order for this patient's definitive care.

  1. 1Perform breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy.
  2. 2Perform a multigene expression assay (e.g., 21-gene recurrence score) on the excised tumor specimen.
  3. 3Administer adjuvant systemic chemotherapy (if indicated by high recurrence risk).
  4. 4Administer adjuvant whole-breast radiation therapy.
  5. 5Initiate long-term adjuvant endocrine therapy (e.g., aromatase inhibitor).

Answer

The correct sequence is: Surgery → Multigene assay → Chemotherapy → Radiation therapy → Endocrine therapy.
The definitive management of early-stage, hormone receptor-positive, HER2-negative breast cancer follows a specific chronological sequence to optimize survival and minimize toxicity. Breast-conserving surgery with sentinel lymph node biopsy is performed first for local control and staging. The excised tumor tissue is then sent for multigene expression profiling (e.g., 21-gene assay) to determine the risk of distant recurrence and the expected benefit of chemotherapy. If chemotherapy is indicated, it is administered prior to radiation therapy to promptly address any systemic micrometastatic disease. Following the completion of chemotherapy, whole-breast radiation therapy is administered to eliminate any residual local microscopic disease, which is a mandatory component of breast-conserving therapy. Finally, adjuvant endocrine therapy (e.g., an aromatase inhibitor) is initiated for long-term suppression of estrogen-stimulated micrometastases.

Step-by-Step Solution

1
Identify the patient's diagnosis and chosen treatment pathway.
The patient has early-stage ER+/PR+/HER2- breast cancer and desires breast-conserving therapy.
This establishes the need for surgery followed by a sequence of adjuvant treatments to prevent local and systemic recurrence.
2
Determine the initial intervention.
Breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy is the first step.
For early-stage, clinically node-negative disease without indications for neoadjuvant therapy, upfront surgical resection and axillary staging are standard.
3
Determine how to risk-stratify the tumor for systemic therapy.
Perform a multigene expression assay on the surgical specimen.
In ER+/HER2- early-stage breast cancer, a multigene assay (e.g., 21-gene Oncotype DX) is performed on the excised tissue to guide the decision for adjuvant chemotherapy.
4
Sequence the adjuvant therapies.
Chemotherapy (if indicated) → Radiation therapy → Endocrine therapy.
Systemic chemotherapy must be given first to target micrometastases early. Radiation follows to consolidate local control. Endocrine therapy provides long-term systemic suppression and typically follows chemotherapy.

Key Concept

The standard sequence of breast-conserving therapy for early-stage hormone-receptor-positive breast cancer is upfront surgery, followed by multigene assay risk stratification, then chemotherapy (if indicated), followed by whole-breast radiation, and finally long-term endocrine therapy.
Rate this question

Topics

Breast Disorders

More questions from this topic